Sean Bohen is CEO & President at Olema Pharmaceuticals, Inc. (OLMA). They have made 4 open-market trades across 1 company since 2021, most recently 2025-12-26.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| OLMA | 237,650 | $2.3M |
Shares reported on the most recent Form 4, priced at the 2025-12-30 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OLMA | SELL | 2024-12-10 | 2024-12-11 | $9.01 | $2.0M | -24.9% | -39.9% | -48.4% |
| OLMA | SELL | 2023-11-21 | 2023-11-22 | $14.38 | $1.6M | -5.4% | +1.0% | +5.1% |
| OLMA | SELL | 2021-10-14 | 2021-10-15 | $30.45 | $294K | -8.4% | -10.2% | -77.6% |
| OLMA | SELL · 10b5-1 | 2021-09-27 | 2021-09-29 | $30.07 | $33K | -1.5% | -7.1% | -67.1% |
| OLMA | SELL | 2021-09-07 | 2021-09-09 | $30.01 | $91K | -5.0% | -2.5% | -60.4% |
| OLMA | SELL · 10b5-1 | 2021-09-01 | 2021-09-03 | $30.05 | $26K | -1.8% | -2.4% | -67.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.